Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China.

Front Oncol · 2026 · PMC12926132 · PMID 41737488

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

50%) and showed a trend toward better survival outcomes in high-risk NB (2-year EFS: 90.9% vs. 51.4%; 2-year OS: 100% vs. 88.9%).

also in 53,322 other papers

nominally significantno p-value reported

Two-sided p < 0.05 was considered nominally significant. 3.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.